Name：YAO Hongjuan

Department：Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

Tel: (8610)63153390

Email: yaohongjuan@imb.pumc.edu.cn

Education & Research Experience

2017/09 – Present Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2016/09 – 2017/09 Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2011/11 – 2016/09 Postdoctoral Fellow, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences

2008/09 – 2011/07 Ph.D., School of Pharmaceutical Sciences, Peking University

2003/08 – 2008/08 Assistant Professor, Institute of Process Engineering, Chinese Academy of Sciences

2000/09 – 2003/07 M.Sc., Department of Chemical Engineering, Tsinghua University

1996/09 – 2000-07B.Sc., Department of Chemical Engineering, Nanjing Tech University

Research Field：

Targeting drug delivery system and tumor pharmacology

Research Interests：

Dr. Yao focuses his research interest on targeting drug delivery system for anticancer therapy, multidrug resistance of cancer, cancer stem cells and tumor-derived exosomes.

Selected Publications

1. Yao HJ, Sun L, Li JC, Zhou XF, Li R, Shao RG, Zhang YG, Li L. A novel therapeutic siRNA nanoparticle designed for dual-Targeting CD44 and Gli1 of gastric cancer stem cells. Int J Nanomedicine. 2020, 15: 7013-7034.

2. Yao HJ, Sun L, Liu Y, Jiang S, Pu YZ, Li JC, Zhang YG. Monodistearoylphosphatidylethanolamine-hyaluronic acid functionalization of single-walled carbon nanotubes for targeting intracellular drug delivery to overcome multidrug resistance of cancer cells. Carbon. 2016, 96: 362-376.

3. Yao HJ, Zhang YG, Sun L, Liu Y. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials. 2014, 35(33): 9208-9223.

4. Yao HJ, Ju RJ, Wang XX, Zhang Y, Li RJ, Yu Y, Zhang L, Lu WL. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery, Biomaterials, 2011, 32(12): 3285-3302.

5. Song WP, Zheng S, Yao HJ, Zhou XF, Li R, Zhang CY, Zhao JY, Wang LW, Shao RG, Li L. Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism. BMC Ophthalmol. 2020, 20(1): 92.

6. Li R, Zhou XF, Yao HJ, Li L. Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. J Drug Target. 2020, 28(9):861-872.

7. Li JC, Sun L, Liu Y, Yao HJ, Jiang S, Pu YZ, Li YJ, Zhang YG. To reduce premature drug release while ensuring burst intracellular drug release of solid lipid nanoparticle-based drug delivery system with clathrin modification. Nanomedicine.2019, 15(1): 108-118

8. Cao R, Song WP, Ye C, Liu XJ, Li L, Li Y, Yao HJ, Zhou XF, Li L, Shao RG. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer. Cancer Med. 2019, 8(2):643-655.